Essentially, it is a hidden bureaucratic inefficiency tax on the whole effort of finding new and valuable therapies, drug development is global and we need to have safety and efficacy data globally, so we should have a global system, just like with airplanes.

Elias Zerhouni

Categorized in : Company News

Last but not least, I would say you should have big dreams, full dreams, not half dreams. You know, it's very simple. You can't put a large box in a small box. Well, you cannot put a full life in a small dream box.

simple dream graduation

It is the responsibility of those of us involved in today's biomedical research enterprise to translate the remarkable scientiﬁc innovations we are witnessing into health gains for the nation. At no other time has the need for a robust, bidirectional information ﬂow between basic and translational scientists been so necessary.

innovation information responsibility

He fits perfectly for us at this time, we have the luxury of a full late-stage pipeline and therefore we can step back and invest for the long term.

Immuno-oncology is just at the beginning of its development, frankly, I think it won't be enough to just remove a checkpoint inhibitor because it is also important to activate the immune system.

There are increasing regulatory differences across the regions, it imposes an enormous cost on the innovator. I spend 20 percent of our R&D budget trying to mix and match in order to do the convergence between different systems.

In my short experience of five years, I have not seen a single regulatory decision that was fully consistent across regulatory agencies.